Quick Answer
REGENERON PHARMACEUTICALS, INC. reported Operating Income of $3.58 billion for fiscal year 2025.
REGENERON PHARMACEUTICALS, INC. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | $3.58B | -10.3% |
| 2024 | $3.99B | -1.4% |
| 2023 | $4.05B | -14.6% |
| 2022 | $4.74B | -47.0% |
| 2021 | $8.95B | +150.1% |
| 2020 | $3.58B | +61.9% |
| 2019 | $2.21B | -12.8% |
| 2018 | $2.53B | +21.9% |
| 2017 | $2.08B | +56.3% |
| 2016 | $1.33B | +6.3% |
| 2015 | $1.25B | +51.9% |
| 2014 | $823.92M | +10.9% |
| 2013 | $743.05M | +62.3% |
| 2012 | $457.71M | +323.1% |
| 2011 | -$205.16M | -110.5% |
| 2010 | -$97.47M | -31.5% |
| 2009 | -$74.10M | +14.1% |
| 2008 | -$86.25M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.03B | -12.9% | -4.9% |
| June 30, 2025 | $1.08B | +0.9% | +82.4% |
| March 31, 2025 | $591.70M | -21.3% | -49.8% |
| September 30, 2024 | $1.18B | +6.2% | +10.3% |
| June 30, 2024 | $1.07B | +5.2% | +42.3% |
| March 31, 2024 | $751.40M | -20.6% | -32.4% |
| September 30, 2023 | $1.11B | -9.2% | +9.3% |
| June 30, 2023 | $1.02B | -8.4% | +7.4% |
- REGENERON PHARMACEUTICALS, INC. showed a decrease of -10.3% in Operating Income compared to the prior fiscal year.
- Over the 2008–2025 period, REGENERON PHARMACEUTICALS, INC.’s operating income has grown by 4248.3% (from -$86.25 million to $3.58 billion).
- The most recent figure is from REGENERON PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 4, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: